TD Cowen analyst Joshua Jennings lowered the firm’s price target on Procept BioRobotics (PRCT) to $34 from $50 and keeps a Buy rating on the shares. The firm updated its model after posting disappointing Q4 results and a steep cut to guidance that was previously viewed as conservative. Q4 sales missed the Street target by over $17M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $28 from $50 at Piper Sandler
- PROCEPT BioRobotics Highlights Growth Strategy at Investor Day
- Procept BioRobotics sees FY26 revenue growth 27%-33%
- Procept BioRobotics downgraded to Perform from Outperform at Oppenheimer
- Procept BioRobotics price target lowered to $34 from $51 at Wells Fargo